Text Size

Evaluation of Diabetes Care at Austrian GPs (DCA09)

This study has been terminated.
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00979394
First received: September 17, 2009
Last updated: August 16, 2010
Last verified: August 2010
History of Changes
  Purpose

This registery should show the medical care of patient with Type 2 Diabetes (T2D) at GP-offices. Furthermore data of co morbidities and risk factors should be evaluated. Objectives of this NIS (cross-sectional study) are:

  • To evaluate which characteristics or co-morbidities are being existent for patient with T2D at GP level,
  • To evaluate representative profile of patient with T2D in Austria,
  • To evaluate which medical therapies are used.

Condition
Type 2 Diabetes

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Diabetes Care Austria 2009

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Evaluate characteristics or co morbidities being existent for patient with T2D at GP [ Time Frame: Once per patient ] [ Designated as safety issue: No ]

Enrollment: 1513
Study Start Date: October 2009
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Patients with type 2 diabetes

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

GPs

Criteria

Inclusion Criteria:

  • Diabetes mellitus type II

Exclusion Criteria:

  • Diabetes mellitus type I
  • Gestation diabetes
  • Induced diabetes
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00979394

Sponsors and Collaborators
AstraZeneca
Bristol-Myers Squibb
Investigators
Study Chair: Bernhard Ludvig General Hospital Vienna
Study Chair: Guntram Schernthaner Krankenanstalt Rudolfsstiftung
  More Information

No publications provided

Responsible Party: MC MD, AstraZeneca
ClinicalTrials.gov Identifier: NCT00979394     History of Changes
Other Study ID Numbers: NIS-CAT-DUM-2009/1
Study First Received: September 17, 2009
Last Updated: August 16, 2010
Health Authority: Austria: Ethikkommission

Keywords provided by AstraZeneca:
Diabetes Care at GPs in Austria
Characteristic of diabetes patients at GPs in Austria

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on May 16, 2013